|
rs1353702185
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We investigated the effects of the germ-line single nucleotide polymorphisms TP53 R72P (215G>C) and MDM2 SNP309 (-410T>G), and p53 protein expression in breast tumors on survival.
|
20021639 |
2009 |
|
rs587781858
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We investigated the effects of the germ-line single nucleotide polymorphisms TP53 R72P (215G>C) and MDM2 SNP309 (-410T>G), and p53 protein expression in breast tumors on survival.
|
20021639 |
2009 |
|
rs753535070
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The MUC1 568 A/G polymorphism strongly influences CA 15-3 levels in healthy women and women with either benign or malignant breast tumors.
|
19121298 |
2009 |
|
rs1056892
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Another variant CBR3 730G>A was associated with higher doxorubicinol AUC (P=0.009, GG vs. AA) and CBR3 expression in breast tumor tissue (P=0.001, GG vs AA).
|
18551042 |
2008 |
|
rs1239905891
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The purposes of this study were to analyse the genotype of TGF-beta1 at T29C and TGF-beta1 phenotype in breast tumours, and to evaluate their associations with IGFs and clinical characteristics of breast cancer.
|
18827819 |
2008 |
|
rs1800470
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The purposes of this study were to analyse the genotype of TGF-beta1 at T29C and TGF-beta1 phenotype in breast tumours, and to evaluate their associations with IGFs and clinical characteristics of breast cancer.
|
18827819 |
2008 |
|
rs35490896
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A separate analysis of the CLSPN c.3839C>T (rs35490896) variant that was observed more frequently in breast tumors than in pancreatic tumors or normal controls failed to detect a significant association with breast cancer risk in a Mayo Clinic breast cancer case-control study.
|
18281469 |
2008 |
|
rs8133052
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A common CBR3 11G>A variant was associated with lower doxorubicinol area under the concentration-time curve (AUC)/doxorubicin AUC metabolite ratio (P=0.009, GG vs. AA; trend test, P=0.004), lower CBR3 expression in breast tumor tissue (P=0.001, GG vs. AA), greater tumor reduction (P=0.015, GG vs. AA), and greater percentage reduction of leukocyte and platelet counts at nadir (trend test, P < or = 0.03).
|
18551042 |
2008 |
|
rs984257990
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The purposes of this study were to analyse the genotype of TGF-beta1 at T29C and TGF-beta1 phenotype in breast tumours, and to evaluate their associations with IGFs and clinical characteristics of breast cancer.
|
18827819 |
2008 |
|
rs146312682
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The rare Ser255Arg variant was identified in only sporadic breast tumors (2/165 tumors).
|
17889706 |
2007 |
|
rs28997576
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Cys557Ser carriers, with or without the BRCA2 mutation, had an increased risk of subsequent primary breast tumors after the first breast cancer diagnosis compared to non-carriers.
|
16768547 |
2006 |
|
rs41293463
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This association was much weaker with the same fragment bearing a missense mutation (M1775R) that has been identified in breast tumors.
|
10403822 |
1999 |
|
rs17879961
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our analyses suggest that there are fundamental differences in breast tumors of CHEK2:p.I157T and c.1100delC carriers.
|
27716369 |
2016 |
|
rs11249433
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our results in two independent data sets suggest that rs11249433, which is located between the NOTCH2 and FCGR1B genes within the 1p11.2 locus, is more strongly associated with risk of breast tumors with low or absent E-cadherin expression, and suggest that evaluation of E-cadherin tumor tissue expression may be useful in clarifying breast cancer risk factor associations.
|
24292867 |
2014 |
|
rs17879961
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We found an even stronger significant association between the CHEK2 I157T C variant and increased risk of lobular type breast tumors (OR = 4.17, 95% CI = 2.89-6.03, P < 0.0001).
|
22799331 |
2012 |
|
rs11249433
|
|
|
0.020 |
GeneticVariation |
BEFREE |
This is the first study to show that the expression of NOTCH2 differs in subgroups of breast tumors and by genotypes of the breast cancer-associated SNP rs11249433.
|
20482849 |
2010 |
|
rs1131691014
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We investigated the effects of the germ-line single nucleotide polymorphisms TP53 R72P (215G>C) and MDM2 SNP309 (-410T>G), and p53 protein expression in breast tumors on survival.
|
20021639 |
2009 |
|
rs878854066
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We investigated the effects of the germ-line single nucleotide polymorphisms TP53 R72P (215G>C) and MDM2 SNP309 (-410T>G), and p53 protein expression in breast tumors on survival.
|
20021639 |
2009 |
|
rs1131691014
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our aim was to evaluate association of R72P with breast cancer risk as well as histopathologic features of the breast tumors and survival.
|
16033823 |
2005 |
|
rs878854066
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our aim was to evaluate association of R72P with breast cancer risk as well as histopathologic features of the breast tumors and survival.
|
16033823 |
2005 |
|
rs1042522
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Taken together, we showed the preferential loss of the rs1042522 C allele, which is protective against BC progression, in breast tumors.
|
21810023 |
2011 |
|
rs1042522
|
|
|
0.030 |
GeneticVariation |
BEFREE |
We investigated the effects of the germ-line single nucleotide polymorphisms TP53 R72P (215G>C) and MDM2 SNP309 (-410T>G), and p53 protein expression in breast tumors on survival.
|
20021639 |
2009 |
|
rs1462893414
|
|
|
0.030 |
GeneticVariation |
BEFREE |
These preliminary results suggest that OCs may interact with the ESR1 A908G mutant receptor to drive the development of some breast tumors.
|
17553133 |
2007 |
|
rs1462893414
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Consistent with our previous finding of this somatic ERalpha mutation in breast ductal hyperplasias, we now present evidence that the A908G mutation is present in invasive breast tumors using an optimized sequencing method.
|
17545528 |
2007 |
|
rs1042522
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Our aim was to evaluate association of R72P with breast cancer risk as well as histopathologic features of the breast tumors and survival.
|
16033823 |
2005 |